ABSTRACT
This study's objective was to determine the effects of increasing the dietary added zinc (Zn) on the milk production, milk somatic cell count (SCC), and immunoglobulin and antioxidant marker concentrations in the blood of dairy cows. Twelve Holstein cows (67 ± 2.5 days in milk) were assigned randomly to (1) a diet containing Zn-methionine at 76 mg/kg of DM (CTL) or (2) CTL top-dressed with about 21 mg/kg of DM extra Zn-methionine (+Zn) for 70 d. The concentrations of reduced (GSH) and oxidized (GSSG) glutathione, malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD), and immunoglobulins in the blood were measured on d 0, 35, and 70. Compared to CTL, +Zn decreased the dry matter intake (DMI) throughout the trial and the milk yield (MY) during the first phase of feeding (0-35 d). It, however, increased the milk yield during the last phase (36-70 d). The +Zn tended to have lower and greater milk protein yields than CTL during the first and last feeding phases, respectively. The +Zn tended to decrease the SCC and was associated with lower plasma GSH: GSSG and lower serum SOD concentrations relative to CTL. The +Zn did not affect the immunoglobulins, MDA, or CAT. Despite the early DMI and MY reduction, the prolonged Zn-methionine supplementation at about 100 mg/kg of DM improved the milk yield, possibly as a result of the improved udder health of dairy cows.
ABSTRACT
HPV vaccination of adolescent girls is the most effective measure to prevent cervical cancer. The World Health Organization recommends that adolescent girls receive two doses of vaccine but only a small proportion of girls from regions with the highest disease burden are vaccinated because of cost and logistical considerations. Our Costa Rica HPV Vaccine trial suggested that one dose of the bivalent HPV vaccine provides robust and lasting protection against persistent HPV infections for over a decade. Data from a post-licensure trial of the quadrivalent vaccine in India also suggested that a single dose may be effective in reducing cervical cancer risk. To formally compare one versus two doses of the bivalent and nonavalent HPV vaccines, we implemented a large, randomized, double-blind trial to investigate the non-inferiority of one compared to two vaccine doses in the prevention of new HPV16/18 infections that persist 6 or more months. Bivalent and nonavalent vaccines will be evaluated separately. The trial enrolled and randomized (1:1:1:1 to 1- and 2-dose arms of the bivalent and nonavalent vaccines) 20,330 girls 12 to 16 years old residing in Costa Rica. Trial participants are followed every 6 months for up to 5 years. We also aim to estimate vaccine efficacy by comparing the rates of 6 month persistent infection in unvaccinated women with the rates in the follow-up visits of trial participants. We included one survey of unvaccinated women at the start of the study (N = 4452) and will include another survey concomitant with follow up visits of trial participants at year 4.5 (planned N = 3000). Survey participants attend two visits 6 months appart. Herein, we present the rationale, design, and enrolled study population of the ESCUDDO trial. ClinicalTrials.gov Identifier: NCT03180034.
